WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012101043) PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/101043    International Application No.:    PCT/EP2012/050830
Publication Date: 02.08.2012 International Filing Date: 20.01.2012
IPC:
C07D 403/12 (2006.01), C07D 407/12 (2006.01), C07D 409/12 (2006.01), A61K 31/4155 (2006.01), A61P 29/00 (2006.01)
Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Corporate Patents Binger Str. 173 55216 Ingelheim am Rhein (DE) (For All Designated States Except US).
ANDERSKEWITZ, Ralf [DE/DE]; (DE) (For US Only).
MARTYRES, Domnic [GB/DE]; (DE) (For US Only).
OOST, Thorsten [DE/DE]; (DE) (For US Only).
RIST, Wolfgang [DE/DE]; (DE) (For US Only).
SEITHER, Peter [DE/DE]; (DE) (For US Only)
Inventors: ANDERSKEWITZ, Ralf; (DE).
MARTYRES, Domnic; (DE).
OOST, Thorsten; (DE).
RIST, Wolfgang; (DE).
SEITHER, Peter; (DE)
Agent: WEYMANN, Markus; Boehringer Ingelheim Pharma GmbH & Co. KG Corporate Patents Binger Str. 173 55216 Ingelheim am Rhein (DE)
Priority Data:
11151876.7 24.01.2011 EP
Title (EN) PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS
(FR) COMPOSÉS DE PYRAZOLE EN TANT QU'ANTAGONISTES DE CRTH2
Abstract: front page image
(EN)The present invention relates to pyrazole compounds of formula (1a) or (1b) and pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Y1, y2, y3, y4, y5, Z, R1, R2, n and R3 have one of the meanings as indicated in the specification and claims, to their use as medicaments, to pharmaceutical formulation containing said compounds and to pharmaceutical formulations said compounds in combination with one or more active substances. The compounds have CRTH2 antagonistic activity.
(FR)Composés de pyrazole représentés par la formule (1a) ou (1b) et sels pharmaceutiquement acceptables de ces composés, formules dans lesquelles Ra, Rb, Rc, Rd, Y1, y2, y3, y4, y5, Z, R1, R2, n et R3 sont comme définis dans les spécifications et les revendications, leurs utilisations comme médicaments, des préparations pharmaceutiques contenant lesdits composés et des préparations pharmaceutiques des dits composés combinées à un ou plusieurs principes actifs. Ces composés possèdent une activité antagoniste à CTRH2.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)